Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

On December 20, 2024, the US Court of Appeals for the Federal Circuit released its opinion in Teva Branded Pharm. Prods. R&D, Inc. v. Amneal ...

In conclusion, the Easyhaler ® more closely demonstrates the characteristics of an ‘ideal inhaler' than its competitors (consistent fine particle dose, performance regardless of inspiration ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

Triple therapy of an inhaled corticosteroid, long acting β 2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more effective in reducing the annual rate of exacerbations compared with ...

Leak Rate. It is common for MDIs to lose propellant during storage. The propellant-leak rate of the test MDIs was compared with that of the controls (Figure 3). The leak rates for the Proventil ...

The listing of patents in the Orange Book has an important role in intellectual property protection for pharmaceuticals. Patents listed in the Orange Book can include, without question, patents ...

Dec 20 (Reuters) - Teva Pharmaceuticals (TEVA.TA), opens new tab failed to convince a U.S. appeals court on Friday to reverse a decision that would remove patents related to its ProAir HFA inhaler ...

Ashley Lowe, PhD, is an assistant professor at the U of A College of Nursing and a member of the U of A Health Sciences Asthma and Airway Disease Research Center. A University of Arizona Health ...

A device costing just pennies, based on an idea by a University of Manchester Professor to help his son use an inhaler, could be a gamechanger for asthma patients. The impressive results are from ...